homovanillic acid has been researched along with MPTP Neurotoxicity Syndrome in 87 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks." | 1.39 | Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ( Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013) |
| " We thus observed the influence of deficiency of complement 3 (C3), the key component of complement system, on the death of dopaminergic neurons in substantia nigra pars compacta (SNpc) and the loss of dopaminergic fibers in striatum induced by acute or chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.34 | Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. ( Guo, Q; Li, S; Liang, Y; Su, B; Wen, C; Zhang, Y; Zou, Q, 2007) |
| "The psychostimulant methamphetamine (MA) is toxic to nigro-striatal dopaminergic terminals in both experimental animals and humans." | 1.32 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. ( Battaglia, G; Busceti, CL; De Blasi, A; Fornai, F; Lembo, G; Nicoletti, F, 2003) |
| " Protection was more profound with an acute dosing regimen than with daily MPTP administration over 5 d." | 1.30 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. ( Beal, MF; Hyman, BT; Klockgether, T; Liao, AW; Martinou, JC; Matthews, RT; Penney, JB; Schulz, JB; Yang, L, 1998) |
| " Recent evidence has demonstrated that chronic administration of MPTP can lead to apoptotic cell death." | 1.30 | Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. ( Andreassen, O; Beal, MF; Ferrante, RJ; Friedlander, RM; Klevenyi, P; Schleicher, JR, 1999) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| " MPTP produced a slight but significant decrease of DA only 4 hours post dosing on PND 23." | 1.29 | Age-related susceptibility to MPTP-induced neurotoxicity in mice. ( Ali, SF; David, SN; Newport, GD, 1993) |
| " The results suggest that the selected dosage schedule produces a widespread and lasting neuronal degeneration closely resembling the neurochemical pathology of Parkinson's disease." | 1.28 | Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. ( De Ceballos, ML; Del Río, J; Herrero, MT; Luquin, MR; Obeso, JA; Oset, C; Pérez-Otaño, I, 1991) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| " It is proposed that the retinal dopaminergic system is less sensitive to the toxic effects of MPTP than the nigro-striatal pathway." | 1.28 | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence. ( Di Paolo, T; Harnois, C; Marcotte, G, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.45) | 18.7374 |
| 1990's | 34 (39.08) | 18.2507 |
| 2000's | 29 (33.33) | 29.6817 |
| 2010's | 21 (24.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, M | 1 |
| Liu, C | 1 |
| Fan, Y | 1 |
| Shi, D | 1 |
| Jian, W | 1 |
| Moreno-Galarza, N | 1 |
| Mendieta, L | 1 |
| Palafox-Sánchez, V | 1 |
| Herrando-Grabulosa, M | 1 |
| Gil, C | 1 |
| Limón, DI | 1 |
| Aguilera, J | 1 |
| Breckenridge, CB | 1 |
| Sturgess, NC | 1 |
| Butt, M | 1 |
| Wolf, JC | 1 |
| Zadory, D | 1 |
| Beck, M | 1 |
| Mathews, JM | 1 |
| Tisdel, MO | 1 |
| Minnema, D | 1 |
| Travis, KZ | 1 |
| Cook, AR | 1 |
| Botham, PA | 1 |
| Smith, LL | 1 |
| Jones, BC | 2 |
| Miller, DB | 2 |
| O'Callaghan, JP | 2 |
| Lu, L | 2 |
| Unger, EL | 1 |
| Alam, G | 2 |
| Williams, RW | 2 |
| Sai, T | 1 |
| Uchida, K | 1 |
| Nakayama, H | 1 |
| Miao, SH | 1 |
| Sun, HB | 1 |
| Ye, Y | 1 |
| Yang, JJ | 1 |
| Shi, YW | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Zhou, JW | 1 |
| Pifl, C | 1 |
| Rajput, A | 1 |
| Reither, H | 1 |
| Blesa, J | 1 |
| Cavada, C | 1 |
| Obeso, JA | 4 |
| Rajput, AH | 1 |
| Hornykiewicz, O | 1 |
| Litim, N | 1 |
| Bourque, M | 1 |
| Al Sweidi, S | 1 |
| Morissette, M | 5 |
| Di Paolo, T | 6 |
| Moraes, LS | 1 |
| Rohor, BZ | 1 |
| Areal, LB | 2 |
| Pereira, EV | 1 |
| Santos, AM | 1 |
| Facundo, VA | 1 |
| Santos, AR | 1 |
| Pires, RG | 2 |
| Martins-Silva, C | 2 |
| Hilario, WF | 1 |
| Herlinger, AL | 1 |
| de Moraes, LS | 1 |
| Ferreira, TA | 1 |
| Andrade, TE | 1 |
| Torok, R | 1 |
| Salamon, A | 1 |
| Sumegi, E | 1 |
| Zadori, D | 1 |
| Veres, G | 1 |
| Molnar, MF | 1 |
| Vecsei, L | 1 |
| Klivenyi, P | 4 |
| Yokoyama, H | 4 |
| Yano, R | 2 |
| Aoki, E | 1 |
| Kato, H | 6 |
| Araki, T | 6 |
| Ookubo, M | 2 |
| Takagi, S | 1 |
| Kuroiwa, H | 1 |
| Viaggi, C | 1 |
| Vaglini, F | 3 |
| Pardini, C | 2 |
| Caramelli, A | 1 |
| Corsini, GU | 3 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Przybylkowski, A | 1 |
| Czlonkowska, A | 1 |
| Czlonkowski, A | 1 |
| Gal, S | 1 |
| Zheng, H | 1 |
| Fridkin, M | 1 |
| Youdim, MB | 1 |
| Han, B | 1 |
| Zhao, H | 1 |
| Zhang, HN | 2 |
| An, CN | 1 |
| Pu, XP | 1 |
| Khan, HA | 1 |
| Gao, L | 1 |
| Díaz-Martín, J | 1 |
| Dillmann, WH | 1 |
| López-Barneo, J | 1 |
| Morrow, BA | 1 |
| Roth, RH | 3 |
| Redmond, DE | 3 |
| Diano, S | 1 |
| Elsworth, JD | 3 |
| Schumm, S | 1 |
| Sebban, C | 1 |
| Cohen-Salmon, C | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Golmard, JL | 1 |
| Boussicault, L | 1 |
| Petropoulos, I | 1 |
| Hild, A | 1 |
| Rousselet, E | 1 |
| Prigent, A | 1 |
| Friguet, B | 1 |
| Mariani, J | 1 |
| Hirsch, EC | 1 |
| Choi, DY | 1 |
| Lee, MK | 1 |
| Hong, JT | 1 |
| Crabtree, D | 1 |
| Boyer-Guittaut, M | 1 |
| Ouyang, X | 1 |
| Fineberg, N | 1 |
| Zhang, J | 1 |
| Ekue, A | 1 |
| Boulanger, JF | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 4 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Bonuccelli, U | 2 |
| Maggio, R | 2 |
| Battaglia, G | 2 |
| Busceti, CL | 2 |
| Lembo, G | 1 |
| Nicoletti, F | 2 |
| De Blasi, A | 1 |
| Obuchowicz, E | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Romańska, I | 1 |
| Herman, ZS | 1 |
| Molinaro, G | 1 |
| Biagioni, F | 1 |
| Storto, M | 1 |
| Bruno, V | 1 |
| Calingasan, NY | 3 |
| Starkov, A | 1 |
| Stavrovskaya, IG | 1 |
| Kristal, BS | 1 |
| Yang, L | 4 |
| Wieringa, B | 1 |
| Beal, MF | 6 |
| Kurosaki, R | 1 |
| Oki, C | 1 |
| Rommelfanger, KS | 1 |
| Weinshenker, D | 1 |
| Miller, GW | 1 |
| D'Astous, M | 1 |
| Callier, S | 2 |
| Shimoji, M | 1 |
| Zhang, L | 1 |
| Mandir, AS | 1 |
| Dawson, VL | 2 |
| Dawson, TM | 2 |
| Gardian, G | 1 |
| von Borstel, R | 1 |
| Saydoff, J | 1 |
| Browne, SE | 1 |
| Shepherd, KR | 1 |
| Lee, ES | 1 |
| Schmued, L | 1 |
| Jiao, Y | 1 |
| Ali, SF | 5 |
| Oriaku, ET | 1 |
| Lamango, NS | 1 |
| Soliman, KF | 1 |
| Charlton, CG | 1 |
| Liang, Y | 1 |
| Li, S | 1 |
| Guo, Q | 1 |
| Zhang, Y | 2 |
| Wen, C | 1 |
| Zou, Q | 1 |
| Su, B | 1 |
| Watanabe, Y | 1 |
| Lorenzo, BJ | 1 |
| Blanchet, J | 1 |
| Longpré, F | 1 |
| Bureau, G | 1 |
| DiPaolo, T | 1 |
| Bronchti, G | 1 |
| Martinoli, MG | 1 |
| Pérez-Otaño, I | 3 |
| Luquin, MR | 3 |
| Oset, C | 3 |
| Herrero, MT | 3 |
| Kupsch, A | 1 |
| Oertel, W | 1 |
| Del Río, J | 3 |
| Fascetti, F | 1 |
| David, SN | 2 |
| Newport, GD | 2 |
| Cadet, JL | 1 |
| Slikker, W | 1 |
| Muthane, U | 1 |
| Ramsay, KA | 1 |
| Jiang, H | 1 |
| Jackson-Lewis, V | 2 |
| Donaldson, D | 1 |
| Fernando, S | 1 |
| Ferreira, M | 1 |
| Przedborski, S | 3 |
| Vizuete, ML | 1 |
| Steffen, V | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Albanese, A | 1 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Oishi, T | 1 |
| Hasegawa, E | 1 |
| Murai, Y | 1 |
| Rose, S | 1 |
| Nomoto, M | 1 |
| Jackson, EA | 1 |
| Gibb, WR | 1 |
| Jaehnig, P | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Rojas, P | 1 |
| Ríos, C | 1 |
| Gainetdinov, RR | 1 |
| Fumagalli, F | 1 |
| Jones, SR | 1 |
| Caron, MG | 1 |
| Schmidt, DE | 1 |
| Ebert, MH | 1 |
| Lynn, JC | 1 |
| Whetsell, WO | 1 |
| Tanila, H | 1 |
| Björklund, M | 1 |
| Riekkinen, P | 1 |
| Mitsumoto, Y | 1 |
| Watanabe, A | 1 |
| Mori, A | 1 |
| Koga, N | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Matthews, RT | 1 |
| Schulz, JB | 1 |
| Klockgether, T | 1 |
| Liao, AW | 1 |
| Martinou, JC | 1 |
| Penney, JB | 1 |
| Hyman, BT | 1 |
| Gerhardt, GA | 1 |
| Cass, WA | 1 |
| Huettl, P | 1 |
| Brock, S | 1 |
| Zhang, Z | 1 |
| Gash, DM | 1 |
| Klevenyi, P | 1 |
| Andreassen, O | 1 |
| Ferrante, RJ | 2 |
| Schleicher, JR | 1 |
| Friedlander, RM | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Itzhak, Y | 1 |
| Martin, JL | 1 |
| Donovan, DM | 1 |
| Miner, LL | 1 |
| Perry, MP | 1 |
| Revay, RS | 1 |
| Sharpe, LG | 1 |
| Kostic, V | 1 |
| Philpot, RM | 1 |
| Kirstein, CL | 1 |
| Rothman, RB | 1 |
| Schindler, CW | 1 |
| Uhl, GR | 1 |
| Andreassen, OA | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Grandbois, M | 1 |
| Bezard, E | 1 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Boireau, A | 1 |
| Bloch, B | 1 |
| Gross, CE | 1 |
| Mandavilli, BS | 1 |
| Van Houten, B | 1 |
| Serra, PA | 1 |
| Sciola, L | 1 |
| Delogu, MR | 1 |
| Spano, A | 1 |
| Monaco, G | 1 |
| Miele, E | 1 |
| Rocchitta, G | 1 |
| Miele, M | 1 |
| Migheli, R | 1 |
| Desole, MS | 1 |
| Fuxe, K | 1 |
| Janson, AM | 1 |
| Rosén, L | 1 |
| Finnman, UB | 1 |
| Tanganelli, S | 1 |
| Morari, M | 1 |
| Goldstein, M | 1 |
| Agnati, LF | 1 |
| Schneider, JS | 1 |
| Nilsson, K | 1 |
| Hallberg, A | 1 |
| Pileblad, E | 1 |
| Tunek, A | 1 |
| Bankiewicz, KS | 1 |
| Plunkett, RJ | 1 |
| Mefford, I | 1 |
| Kopin, IJ | 1 |
| Oldfield, EH | 1 |
| Russ, H | 1 |
| Mihatsch, W | 1 |
| Gerlach, M | 1 |
| Riederer, P | 1 |
| Przuntek, H | 1 |
| Garant, D | 1 |
| Fariello, R | 1 |
| De Ceballos, ML | 1 |
| Bodis-Wollner, I | 1 |
| Chung, E | 1 |
| Ghilardi, MF | 1 |
| Glover, A | 1 |
| Onofrj, M | 1 |
| Pasik, P | 1 |
| Samson, Y | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 1 |
| Carr, LA | 1 |
| Rowell, PP | 1 |
| Deutch, AY | 2 |
| Sladek, JR | 2 |
| Taylor, JR | 1 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Harnois, C | 1 |
| Marcotte, G | 1 |
87 other studies available for homovanillic acid and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Total glucosides of paeony (TGP) extracted from Radix Paeoniae Alba exerts neuroprotective effects in MPTP-induced experimental parkinsonism by regulating the cAMP/PKA/CREB signaling pathway.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; | 2019 |
Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2018 |
Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; B | 2013 |
Systems analysis of genetic variation in MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine; Gene E | 2013 |
Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2013 |
Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Carrier Proteins; Cell Line; Cell Survival; Dis | 2014 |
Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Uptake | 2014 |
The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-alpha Reductase Inhibitors; Animals; Corpus Striatum; Dihydrotesto | 2015 |
Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Combretum; Dopamine; Gene Expression Regulation; Homovanill | 2016 |
MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2016 |
Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Dopamine; Homovanillic Acid; Locomotion; Mal | 2016 |
Effect of MPTP on mRNA expression of PGC-1α in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 2017 |
Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipyrine; Cyclooxygenase Inhibitors; Dopamine; Edaravone; | 2008 |
Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Cytoprotection; Dopamine; Drug Evaluation, | 2008 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astroc | 2009 |
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2009 |
Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Blotting, Western; Chrom | 2009 |
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain Chemistry; Cell Division; Chrom | 2010 |
Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Western; Dopamine; Dopamine Plasma Membrane Trans | 2009 |
Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Chalcone; Corpus Striatum; Dopamine; Glutathione; | 2010 |
Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedu | 2010 |
Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; M | 2010 |
Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2011 |
Susceptibility to a parkinsonian toxin varies during primate development.
Topics: Age Factors; Animals; Chlorocebus aethiops; Corpus Striatum; Dopamine; Homovanillic Acid; MPTP Poiso | 2012 |
Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; An | 2012 |
Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2013 |
Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Cathepsin D; Corpus Striatum; Dopamine | 2013 |
Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Cocaine; Dihydrotestosterone; Dopamine; Do | 2002 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chelating Age | 2003 |
Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-1 Rec | 2003 |
Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Chromatography, High Pressure | 2003 |
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2004 |
Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Monophosphate; Animals; Brain; Brain Chemistry; Chromatogr | 2004 |
Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Cell Communication; Dopamine; Glial | 2004 |
Reduced MPTP toxicity in noradrenaline transporter knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Blotting, Western; Brain Chemistry; C | 2004 |
Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Corpus Striatum; Dopamine; Enkephalins; Es | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Anima | 2005 |
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetates; Animals; Die | 2004 |
The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2006 |
Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Complement C3; Dopami | 2007 |
Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antibodies; Astrocytes; Behavior, Animal; Blotting, Western | 2008 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Animals, Newborn; Cell Count; Disease | 2008 |
Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callithrix; Dopamine; Enkephalin, Methionine; Female | 1995 |
(+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Ditiocarb; Dizocilpine Maleate | 1994 |
MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Dopamine; Homovanillic Acid; Male; Mice; Mice, Inbre | 1994 |
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biomarkers; Calbindin 1; Calbindins; | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
1-Methyl-4-phenylpyridinium has greater neurotoxic effect after selenium deficiency than after vitamin E deficiency in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Dopamine; Eating; Free Radicals; Glutathione P | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1993 |
Age-related susceptibility to MPTP-induced neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Fluoresceins; Homovanillic Acid; | 1993 |
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; Brain Chemistry; Callithrix; Chromatography, | 1993 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Dopami | 1995 |
Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Carrier Proteins; Corpus Striatum; Do | 1997 |
Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn | 1997 |
Cognitive changes in mice following moderate MPTP exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Agonists; Animals; Cerebral Cortex; Cognition; Corp | 1998 |
Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; M | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Brain Chemistry; Ca | 1998 |
GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Metabolism; Dextroamphetamine; Dopamine; Dopamine Age | 1999 |
Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caspase 1; Corpus Striatum; Dopamine; Drug Resistance; Gene | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Carrier Proteins; Dopamine; Dopamine Plas | 1999 |
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasm | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
DNA damage in brain mitochondria caused by aging and MPTP treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; Animals; Brain Chemistry; DNA Damage; DNA, Mitoc | 2000 |
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Corpus Striatum; Dopamine; Glutathione; Homovani | 2002 |
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthesia, General; Animals; Benzhydryl Compounds; Central Nervous | 1992 |
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; | 1992 |
Investigation of the possible dopaminergic toxicity of 1-methyl-3-phenyl-1,2,3,6-tetrahydropyridine, an isomer to the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1991 |
Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites.
Topics: Adrenal Medulla; Amnion; Animals; Brain Tissue Transplantation; Caudate Nucleus; Disease Models, Ani | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
The acute convulsant effect of MPTP is dependent on intracerebral MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1991 |
Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callit | 1991 |
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
Topics: Acetylcarnitine; Animals; Carbidopa; Caudate Nucleus; Electroretinography; Female; Homovanillic Acid | 1991 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1990 |
MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
Topics: Animals; Cercopithecus; Dopamine; Homovanillic Acid; Male; MPTP Poisoning; Parkinson Disease, Second | 1990 |
Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
Topics: Animals; Cercopithecus; Corpus Striatum; Dopamine; Homovanillic Acid; Male; MPTP Poisoning; Parkinso | 1989 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Designer Drugs; Dopamine; Electroretinogra | 1989 |